The latest research findings with participation of the KKNMS

Diagnostik und Therapie von Tuberkulose unter Immuntherapien für Multiple Sklerose
By Bittner et al, published by “Der Nervenarzt” (Vol. 90, no. 12, December 2019)

CD8(+) T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome
By Gross et al, published by “Nat Commun” (December 2019)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
By Keller et al, published by “Ann Clin Transl Neurol” (Vol. 6, no. 12, December 2019)

Human CCR5high effector-memory cells perform CNS parenchymal immune surveillance via Granzyme K- mediated transendothelial diapedesis
By Herich et al, published by “Brain” (Vol. 142, no. 11, November 2019)

Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral
By Mocchia et al, published by “Ann Neurol” (Vol. 86, no. 5, November 2019)

Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases
By Lepennetier et al, published by “J Neuroinflammation” (Vol. 16, no. 219, November 2019)

Stability and Maintenance of Foxp3+ Treg Cells in Non-lymphoid Microenvironments
By Korn et al, published by “Front Immunol” (Vol. 10, November 2019)

Temporal Dynamics of Diffusion Metrics in Early Multiple Sclerosis and Clinically Isolated Syndrome: A 2-Year Follow-Up Tract-Based Spatial Statistics Study
By Schneider et al, published by “Front Neurol” (Vol. 10, no. 1165, November 2019)

Imaging the execution phase of neuroinflammatory disease models
By Schumacher et al, published by “Experimental Neurology” (Vol. 320, October 2019)

Clinical relevant cranio-caudal patterns of cervical cord atrophy evolution in MS
By Rocca et al, published by “Neurology” (October 2019)

Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging
By Schmidt et al, published by “NeuroImage: Clinical” (Vol. 23, 2019)

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
By Schwab et al, published by “Neurology” (Vol. 93, no. 17, September 2019)

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
By International Multiple Sclerosis Genetics Consortium, published by “Science” ( Vol. 365, no. 6460, September 2019)

Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity
By Fecher et al, published by “Nat. Neurosci” (September 2019)

Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion?
By Pongratz et al, published by “Brain Behav” (September 2019)

Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy
By Stengel et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 6, no. 5, September 2019)

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS
By Engel et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 6, no. 5, September 2019)

Dendritic Cell Accumulation in the Gut and Central Nervous System Is Differentially Dependent on α4 Integrins
By Sie et al, published by “J Immunol” (Vol. 203, no. 6, September 2019)

Pretreatment anti-thyroid autoantibodies predict thyroid autoimmunity secondary to alemtuzumab
By Ruck et al, published by “EBioMedicine” (Vol. 46, August 2019)

CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date
By Ancau et al, published by “Expert Opin Biol Ther” (Vol. 19, no. 8, August 2019)

A large case-control study on vaccination as risk factor of multiple sclerosis
By Hapfelmeier et al, published by “Neurology” (Vol. 93, no. 9, August 2019)

Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects
By Weeda et al, published by “Neuroimage Clin” (Vol. 24, August 2019)

Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
By Oertel et al, published by “J Neuroinflammation” (Vol. 16, no. 1, July 2019)

Single-subject structural cortical networks in clinically isolated syndrome
Von Collorone et al, erschienen in “Mult Scler” (July 2019)

Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany
By Bittner et al, published by “Nervenarzt” (July 2019)

Cerebrospinal fluid parameters associated with early MRI activity in patients with multiple sclerosis
By Klein et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 6, no. 4, July 2019)

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis
By Gasperi et al, published by “JAMA Neurol” (Vol. 76, no. 7, July 2019)

MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants
By Schuh et al, published by “Clin Immunol” (Vol. 203, June 2019)

The Glycosylation Site of Myelin Oligodendrocyte Glycoprotein Affects Autoantibody Recognition in a Large Proportion of Patients
By Marti Fernandez et al, published by “Front Immunol” (Vol. 10, June 2019)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
By Haas et al, published by “Front Immunol” (Vol. 19, June 2019)

Immunophenotyping of cerebrospinal fluid cells in ischemic stroke
By Schulte-Mecklenbeck et al, published by “Eur J Neurol” (Vol. 26, no. 6, June 2019)

A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis
By International Multiple Sclerosis Genetics Consortium, published by “Nat Commun” (Vol. 10, no. 1, May 2019)

Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data
By Simbrich et al, published by “Neuropsychiatr Dis Treat” (Vol. 15, May 2019)

Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study
By Nolan-Kenney et al, published by “Ann Neurol” (Vol. 85, no. 5, May 2019)

VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells
By Breuer et al, published by “Int Immunol” (Vol. 31, no. 6, May 2019)

Evidence for a white matter lesion size threshold to support the diagnosis of multiple sclerosis
By Grahl et al, published by “Mult Scler Relat Disord” (Vol. 29, April 2019)

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis
By Graetz et al, published by “Mult Scler” (Vol. 25, no. 5, April 2019)

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials
By Buck et al, published by “Mult Scler” (Vol. 25, no. 4, April 2019)

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment
By Klotz et al, published by “Ther Adv Neurol Disord” (Vol. 12, April 2019)

Abundant glutamic acid decarboxylase (GAD)‐reactive B cells in gad‐antibody–associated neurological disorders
By Thaler et al, published by “Ann Neurol” ( Vol. 85, no. 3, March 2019)

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis
By Kroth et al, published by “Mult Scler” (Vol. 25, no. 3, March 2019)

β-Synuclein reactive T cells induce autoimmune CNS grey matter degeneration
By Lodygin et al, published by “Nature” (Vol.566, February 2019)

Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution
By Masuda et al, published by “Nature” (Vol. 566, no. 7744, February 2019)

Calcium influx trough plasma-membrane nanopores drives axon degeneration in an animal model of multiple sclerosis
By Witte et al, published by “Neuron” (Vol. 101, no. 4, February 2019)

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS)
By Johnen et al, published by “J Neurol” (Vol. 266, no. 2, February 2019)

Blimp1 prevents methylation of Foxp3 and loss of regulatory T cell identity at sites of inflammation
By Garg et al, published by “Cell Rep” (Vol. 26, no. 7, February 2019)

Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis
By Feucht et al, published by “Mult Scler” (Vol. 25, no. 2, February 2019)

Stars are not in outer space: Astrocytes respond to environmental cues
By Korn, published by “Cell” (Vol. 176, no. 3, January 2019)

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
By Pfeuffer et al, published by “J Neurol” (Vol. 266, no.1, January 2019)

Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation
By Jordão et al, published by “Science” (Vol. 363, January 2019)

Myeloid-derived suppressor cells control B cells within the central nervous system during autoimmunity
By Knier et al, published by “Nat Immunol” (Vol. 19, no. 12, December 2018)

Vitiligo after alemtuzumab treatment: autoimmunity is not all about B cells
By Ruck et al, published by “Neurology” (Vol. 91, no. 24, December 2018)

Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study
By Oertel et al, published by “J Neurol Neurosurg Psychiatry” (Vol. 89, no. 12, December 2018)

Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies
By Doppler K et al, published by “J Neurol Neurosurg Psychiatry” (Vol. 89, no. 11, November 2018)

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
By International Multiple Sclerosis Genetics Consortium, published by “Cell” (Vol. 175, no. 6, November 2018)

Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging
By Seitz CB et al, published by “J Neurol” (Vol. 265, no. 10, October 2018)

Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions
By Kleiter I et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 5, no. 6, September 2018)

Shedding of BAFF/APRIL Receptors Controls B Cells
By Meinl E et al, published by “Trends Immunol.” (Vol. 39, no. 9, September 2018)

Neuroimmunologische Register in Deutschland
By Thiel S et al, published by “Akt Neurol” (Vol. 45, no. 01, 2018)

Monuclear phagocytes locally specify and adapt their phenotype in a multiple sclerosis model
By Locatelli et al, published by “N Neuroscience” (no. 21, August 2018)

Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein
By Spadaro M et al, published by “Ann Neurol.” (Vol. 84, no. 2, August 2018)

Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus
By Breuer et al, published by “N Neuroinflamm” (August 2018)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid – Results from the ToFingo Successor Study
By Lohmann L et al, published by “Frontiers in Immunology” (Vol. 9, July 2018)

Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters
By Pongratz (geb. Biberacher) V et al, published by “Multiple Sclerosis” (Vol. 24, no. 8, July 2018)

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis
By Kular L et al, published by “Nat Commun” (Vol. 9, no. 1, June 2018)

Interleukin-6: Designing specific therapeutics for a complex cytokine
By Garbers et al, published by “Nat Rev Drug Discov” (Vol. 17, no. 6, June 2018)

Immunophenotyping of cerebrospinal fluid cells by Chipcytometry
By Hümmert MW et al, published by “Journal of Neuroinflammation” (Vol. 15, no. 1, May 2018)

Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3
By Schmidt A et al, published by “BMC Biol” (Vol. 16, no. 1, May 2018)

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
By Jarius S et al, published by “Journal of Neuroinflammation” (Vol. 15, no. 1, May 2018)

Treatment choices and neuropsychological symptoms of a large cohort of early MS
BY Bismarck O et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 5, no. 3, May 2018)

Autoantibodies Against the Node of Ranvier in Seropositive Cyronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic
By Vural A et al, published by “Front Immunol.” (Vol. 9, May 2018)

Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients
By Huss A et al, published by “Ann Neurol.” (Vol. 83, no. 5, May 2018)

A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation
By Voet et al, published by “Nat Commun” (Vol. 9, no. 1, May 2018)

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS
By Fleischer V et al, published by “Mult Scler” (Vol. 24, no. 5, April 2018)

Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis
By Stork L et al, published by “JAMA Neurology” (Vol. 75, no. 4, April 2018)

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
By Schwab N et al, published by “Multiple Sclerosis” (Vol. 24, no. 5, April 2018)

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials
By Buck et al, published by “Multiple Sclerosis Journal” (doi:10.1177/1352458518763089, March 2018)

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?
By Graetz C et al, published by “Expert Rev Neurother.” (Vol. 18, no. 3, March 2018)

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature
By Jarius S et al, published by “Journal of Neuroinflammation” (Vol. 15, no. 1, March 2018)

Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients
By Kalluri SR et al, published by “J Autoimmun.” (Vol. 88, March 2018)

Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) – Feasibility testing, pilot randomised controlled trial and mixed methods process evaluation
By Rahn Ac et al, published by “International Journal of Nursing Studies” (Vol. 78, February 2018)

Sex bias in MHC I-associated shaping of the adaptive immune system
By Schneider-Hohendorf T et al, published by “Proc Natl Acad Sci U S A.” (Vol. 115, no. 9, February 2018)

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation
By Wiendl H et al, published by “Neurology” (Vol. 90, no. 7, February 2018)

Neuroimmunological Registries in Germany
By Thiel S et al, published by “Neurology International Open 2018” (Vol. 2, no. 1, February 2018)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study
By Riepl E et al, published by “Front Neurol” (Vol. 8; January 2018; eCollection 2017)

IL-23 (Interleukin-23)-Producing Conventional Dendritic Cells Control the Detrimental IL-17 (Interleukin-17) Response in Stroke
By Gelderblom et al, published by “Stroke” (Vol. 49, no 1, January 2018)

Baló’s concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures
By Jarius S et al, published by “Journal of Neuroinflammation” (Vol. 15, no. 1, January 2018)

Incidence of multiple sclerosis in Germany: A cohort study applying different case Definitions based on claims data
By Schmedt et al, published by “Neuroepidemiology” (Vol. 49, Nr. 3-4, December 2017)

Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium
By Breuer et al, published by “Mult Scler” (2017 Oct 1:1352458517735189.)

Cladribine – an old newcomer for pulsed immune reconstitution in MS
By Wiendl, published by “Nat Rev Neurol.” (Vol. 13; no. 10; October 2017)

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice
By Berer et al, published by “Proc Natl Acad Sci U S A.” (Vol. 114, no. 40, October 2017)

A gut feeling about multiple sclerosis
By Quintana and Prinz, published by “Proc Natl Acad Sci U S A.” (Vol. 114, no. 40, October 2017)

Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging
By Righart R et al, published by “Annals of Neurology” (Vol. 82, no. 4, October 2017)

A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease
By Mass et al, published by “Nature” (Vol. 549, no. 7672, September 2017)

A novel imaging technique for better detecting new lesions in multiple sclerosis
By Eichinger P et al, published by “Journal of Neurology” (Vol. 264, no. 9, September 2017)

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
By Wiendl et al, published by “Neurology” (Vol. 89, no. 11, September 2017)

Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner
By Deczkowska et al, published by “Nat Commun” (Vol. 8, no. 1, September 2017)

Type I interferon pathway in CNS homeostasis and neurological disorders
By Blank and Prinz, published by “Glia” (Vol. 65, no. 9, September 2017)

Microglia in steady state
By Kierdorf and Prinz, published by “J Clin Invest” (Vol. 127, no. 9, September 2017)

Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood
By Hagemeyer et al, published by “Acta Neuropathol” (Vol. 134, no. 3, September 2017)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
By Stellmann JP et al, published by “Journal of Neurology, Neurosurgery and Psychiatry” (Vol. 88, no. 8, August 2017)

Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis
By Jarius S et al, published by “Journal of Neuroinflammation” (Vol. 14, no. 1, August 2017)

A new graphical format to communicate treatment effects to patients- a web-based randomized-controlled trial
By Kasper et al, published by “Health Expectations” (Vol. 20, no. 4, August 2017)

Relevance of early cervical cord volume loss in the disease evolution ofclinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study
By Hagström IT et al, published by “Journal of Neurology” (Vol. 264, no. 7, July 2017)

Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients
By Rhigart et al, published by “PLOS ONE” (Vol. 12, no. 7, July 2017)

Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis
By Fleck at al, published by “Int J Mol Sci” (Vol. 18, no. 7, July 2017)

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders
By Borisow N et al, published by “Multiple Sclerosis” (Vol. 23, no. 8, July 2017)

Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis: A cohort study
By Knier B et al, published by “JAMA Neurology” (Vol. 74, no. 7, July 2017)

Daclizumab for the treatment of relapsing-remitting multiple sclerosis
By Herwerth and Hemmer, published by “Expert Opin Biol Ther” (Vol. 17, no. 6, June 2017)

Laquinimod enhances central nervous system barrier functions
By Lühder et al, published by “Neurobiol Dis” (Vol. 102, June 2017)

A new fate mapping system reveals context-dependent random or clonal expansion of microglia
By Tay et al, published by “Nature Neuroscience” (Vol. 20, no. 6, June 2017)

Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets
By Gross et al, published by “Mult Scler” (Vol. 23, no. 7, June 2017)

Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder
By Streitberger et al, published by “Eur Radiol” (Vol. 27, no. 5, May 2017)

Central Atrophy Early in Multiple Sclerosis: Third Ventricle Volumetry versus Planimetry
By Lutz et al, published by “J Neuroimaging” (Vol. 27, no. 3, May 2017)

Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement
By Schuh et al, published by “J Immunol” (Vol. 198, no. 8, April 2017)

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification
By Schwab N et al, published by “Neurology” (Vol. 88, no. 12, March 2017)

Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis
By Fleischer V et al, published by “Multiple Sclerosis” (Vol. 23, no. 3, March 2017)

Ontogeny and homeostasis of CNS myeloid cells
By Prinz et al, published by “Nature Immunology” (Vol. 18, no. 4, March 2017)

Deletional tolerance prevents AQP4 directed autoimmunity in mice
By Vogel AL et al, published by “European Journal of Immunology” (Vol. 47, no. 3, March 2017)

Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis
By Gross CC et al, published by “Proceedings of the National Academy of Science of the USA” (Vol. 114, no. 6, February 2017)

The role of peripheral immune cells in the CNS in steady state and disease
By Prinz and Priller, published by “Nature Neuroscience” (Vol. 20, no. 2, February 2017)

Multiple sclerosis in 2016: Immune-directed therapies in MS – efficacy and limitations
By Hemmer B et al, published by “Nature Reviews. Neurology” (Vol. 13, no. 2, February 2017)

Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
By Haas et al, published by “Mult Scler” (Vol. 23, no. 1, January 2017)

B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis
By Schwarz et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 4, no. 1: e309, January 2017)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
By Gross et al, published by “Front Immunol” (Vol. 7, December 2016, eCollection 2016)

Myeloid Dendritic Cells exhibit Defects in Activation and Function in Patients with Multiple Sclerosis
By Haas, published by “J Neuroimmunol” (Vol. 301, December 2016)

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: A German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome
By Huss et al, published by “J Neurol” (Vol. 263, Nr. 12, December 2016)

Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis
By Huss et al, published by “Expert Review of Molecular Diagnostics” (Vol. 16, Nr. 12, December 2016)

Brain parenchymal damage in neuromyelitis optica spectrum disorder – A multimodal MRI study
By Pache et al, published by “European Radiology” (Vol. 26, Nr. 12, December 2016)

Patientenwiderrufe als Herausforderung für das Datenmanagement – ein Lösungsvorschlag für die Forschungspraxis
By Antony et al, published by “e-Health 2016”

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
By Pache et al, published by “J Neuroinflammation” (Vol. 13, 1, November 2016)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement – frequency, presentation and outcome
By Jarius et al, published by “J Neuroinflammation” (Vol. 13, 1, November 2016)

Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis
By Biberacher et al, published by “Neuroimage” (Vol. 142, November 2016)

Metabolic Patterns in Chronic Multiple Sclerosis Lesions and Normal-appearing White Matter: Intraindividual Comparison by Using 2D MR Spectroscopic Imaging
By Fleischer et al, published by “Radiology” (Vol. 281, No. 2, November 2016)

Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case
By Jarius et al, published by “Multiple Sclerosis Journal” (Vol. 22, No. 12, October 2016)

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: Grey matter atrophy but not lesions are predictive in a real-life setting
By von Gumbertz et al, published by “PeerJ” (Vol. 4: e2442.eCollection, September 2016)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
By Jarius et al, published by “J Neuroinflammation” (Vol. 13, No. 1, September 2016)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
By Jarius et al, published by “J Neuroinflammation” (Vol. 13, No. 1, September 2016)

Comprehension of confidence intervals – development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial
By Rahn et al, published by “BMC Med Inform Decis Mak” (Vol. 16, No. 1, September 2016)

Vascular, glial, and lymphatic immune gateways of the central nervous system
By Engelhardt et al, published by “Acta Neuropathol” (Vol. 132, No. 3, September 2016)

Calibrating random forests for probability estimation
By Dankowski and Ziegler, published by “Stat Med” (Vol. 35, No. 22, September 2016)

CD4+HLA-G+ regulatory T cells: Molecular signature and pathophysiological relevance
By Pankratz et al, published by “Hum Immunol” (Vol. 77, No. 9, September 2016)

Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study
By Schlemm et al, published by “J Neuroimmunol” (Vol. 297, August 2016)

The force awakens: insights into the origin and formation of microglia
By Tay et al, published by “Curr Opin Neurobiol” (Vol. 39, August 2016)

Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study
By Kovacs et al, published by “Multiple Sclerosis Journal” (Vol. 22, Nr. 9, August 2016)

Transcriptome-based profiling of yolk sac-derived macrophage development and identification of a role of Irf8 in their maturation
By Hagemeyer et al, published by “EMBO J.” (Vol. 35, Nr. 16, August 2016)

Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity
By Beer et al, published in “Journal of Neurology” (Vol. 263, Nr. 8, August 2016)

Features of Human CD3+CD20+ T Cells
By Schuh et al, published by “J Immunol.” (Vol. 197, Nr. 4, August 2016)

PML risk stratification using anti-JCV antibody index and L-selectin
By Schwab et al, published by “Multiple Sclerosis Journal” (Vol. 22, Nr. 8, Juli 2016)

Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI
By Chawla et al, published by “AJNR Am J Neuroradiol.” (Vol. 37, Nr. 7, Juli 2016)

MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T
By Sinnecker et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, Nr. 4, Juli 2016)

Origin, fate and dynamics of macrophages at central nervous system interfaces
By Goldmann et al, published by “Nat Immunol.” (Vol. 17, Nr. 7, Juli 2016)

Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie- Substanzspezifische Relevanz und aktuelle Handlungsempfehlungen
By Klotz et al, published by “Nervenarzt” (Vol. 87, no. 6, June 2016)

Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study
By Schumacher et al, published by “MAGMA” (Vol. 29, no. 3, June 2016)

Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer
By Soelberg et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, Nr. 4, Juni 2016)

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
By Spadaro et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, Nr. 5, Juni 2016)

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation
By Andlauer et al, published by “Science Advances” (Vol. 2, Nr. 6, Juni 2016)

Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis
By Otto et al, published by “Med Hypotheses” (Vol. 91, Juni 2016)

Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis
By Haas et al, published by “J Neuroimmunol.” (Vol. 294, Mai 2016)

Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis
Von Halbgebauer et al, erschienen in “J Neurol.” (Vol. 263, Nr. 5, Mai 2016)

In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology
Von Herwerth et al, erschienen in “Ann Neurol.” (Vol. 79, Nr. 5, Mai 2016)

Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis
By Deppe et al, published by “Hum Brain Mapp.” (Vol. 37, Nr. 5, Mai 2016)

Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation
By Gross et al, published by “Proc Natl Acad Sci U S A.” (Vol. 113, Nr. 21, Mai 2016)

Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis
By Liu et al, published by “Am J Neuroradiol.” (Vol. 37, no. 4, April 2016)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
By Finke et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, no. 3, April 2016)

Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study
By Ayzenberg et al, published by “J Neurol.” (Vol. 263, no. 3, March 2016)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
By Schwab et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 3, February 2016)

Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
By Metz et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, no. 2, February 2016)

Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica
By Hertwig et al, published by “Multiple Sclerosis Journal” (Vol. 22, no. 2, February 2016)

Structural correlates for fatigue in early relapsing remitting multiple sclerosis
By Wilting et al, published by “European Radiology” (Vol. 26, no. 2, February 2016)

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses
By Kleiter et al, published by “Ann Neurol.” (Vol. 79, no. 2, February 2016)

Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration
By Deppe et al, published by “Multiple Sclerosis Journal” (Vol. 22, no. 1, January 2016)

Changing requirements and resulting needs for IT-infrastructure for longitudinal research in the neurosciences
By Buckow et al, published by “Neurosci Res.” (Vol. 102, January 2016)

In vivo visualization of (auto)immune processes in the central nervous system of rodents
By Schläger et al, published by “Methods Mol Biol.” (Vol. 1304, 2016)

Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases
By Spadaro M and Meinl E, published by “Methods “Mol Biol.” (Vol. 1304, 2016)

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS
By Schrewe et al, published by “Journal of Neuroinflammation” (Vol. 12, no. 1, December 2015)

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis
By Luessi et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 14, December 2015)

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array
By Dankowski et al, published by “Genet Epidemiol.” (Vol. 39, no. 8, December 2015)

Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis
By Haas et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 12, October 2015)

Putaminal alteration in multiple sclerosis patients with spinal cord lesions
By Zimmermann et al, published by “Journal of Neural Transmission” (Vol. 122, no. 10, October 2015)

Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis
By Keller et al, published by “J Neuroinflammation” (Vol. 12, October 2015)

Class II HLA interactions modulate genetic risk for multiple sclerosis
By Moutsianas et al, published by “Nat Genet.” (Vol. 47, no. 10, October 2015)

Central Role of Th2 and Tc2 Lymphocytes in Multiple Sclerosis Pattern II Demyelinating Lesions
By Planas et al, published by “Annals of Clinical and Translational Neurology” (Vol. 2, no. 9, September 2015)

Relevance of Magnet Resonance Tomography in the Diagnosis and Assessment of Course of Disease in Patients with Multiple Sclerosis
By Lukas C and Sailer M, published by “Fortschr Neurol Psychiatr.” (Vol. 83, no. 9, September 2015)

Magnetresonanztomografie bei Patienten mit Multipler Sklerose: Relevanz in der Diagnose und Verlaufsbeurteilung
By Lukas C and Sailer M, published by “Klin Neurophysiol” (Vol. 46, no. 3, September 2015)

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
By Warnke et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 8, July 2015)

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
By Kuhle et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 8, July 2015)

Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9
By Lindner et al, published by “Brain” (Vol. 138, Pt 7, July 2015)

Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis
By Kolber et al, published by “Journal of Neurology” (Vol. 262, no. 6, June 2015)

γ-secretase directly sheds the survival receptor BCMA from plasma cells
By Laurent et al, published by “Nature Communications” (Vol. 6, June 2015)

Atrophy and structural variability of the upper cervical cord in early multiple sclerosis
By Biberacher et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 7, June 2015)

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases
By Rau et al, published by “Int J Mol Sci.” (Vol. 16, no. 7, June 2015)

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
By Bennett et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 6, May 2015)

B lymphocytes in neuromyelitis optica
By Bennett et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 2, no. 3, May 2015)

A human post-mortem brain model for the standardization of multi-centre MRI studies
By Droby et al, published by “Neuroimage” (Vol. 110, April 2015)

Role of the innate and adaptive immune responses in the course of multiple sclerosis
By Hemmer et al, published by “Lancet Neurology” (Vol. 14, no. 4, April 2015)

Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis
By Metz et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 2, no. 3, April 2015)

Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies–conflicting results?
By Hemmer B., published by “Multiple Sclerosis Journal” (Vol. 21, no. 5, April 2015)

The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients
By Droby et al, published by “NeuroImage: Clinical” (Vol. 8, April 2015)

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc
By Stork et al, published by “Acta Neuropathol.” (Vol. 129, no. 3, March 2015)

Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial
By Rahn et al, published by “Trials” (Vol. 16, no. 1, March 2015)

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
By Spadaro et al, published by “Ann Clin Transl Neurol.” (Vol. 2, no. 3, March 2015)

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
By Villar et al, published by “Ann Neurol.” (Vol. 77, no. 3, March 2015)

Cross-recognition of a myelin peptide by CD8+ T cells in the CNS is not sufficient to promote neuronal damage
By Reuter et al, published by “Journal of Neuroscience” (Vol. 35, no. 12, March 2015)

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria
By Schippling et al, published by “Mult Scler.” (Vol. 21, no. 2, February 2015)
MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4
By Walsh et al, published by “J Clin Invest.” (Vol. 125, no. 2, February 2015)

Fingolimod treatment promotes regulatory phenotype and function of B cells
By Grützke et al, published by “Ann Clin Transl Neurol.” (Vol. 2, no. 2, February 2015)

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b
By Ingwersen et al, published by “Ann Clin Transl Neurol.” (Vol. 2, no. 1, January 2015)

Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands
By Halbgebauer et al, published by “Electrophoresis” (Vol. 36, no. 2, January 2015)

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis
By Grey et al, published by “J Neuroimmunol.” (Vol. 278, January 2015)

The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity
By Hoffmann et al, published by “J Immunol.” (Vol. 194, no. 2, January 2015)

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis
By Schwab et al, published by “Int Immunol.” (Vol. 27, no. 1, January 2015)

The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations
By Kowarik et al, published by “J Neuroinflammation” (Vol. 12, no. 19, January 2015)

Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with MS
By Fleischmann et al, published by “JAMA Neurol.” (Vol. 72, no. 1, January 2015)

Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking
By Posevitz-Fejfár et al, published by “PLoS One” (Vol. 9, no. 12, December 2014)

A recoverable state of axon injury persists for hours after spinal cord contusion in vivo
By Williams et al, published by “Nat Commun.” (Vol. 5, Nr. 5683, December 2014)

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy
By Warnke et al, published by “Ann Neurol.” (Vol. 76, no. 6, December 2014)

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia
By Warnke et al, published by “Neurology” (Vol. 83, no. 23, December 2014)

Pervasive axonal transport deficits in multiple sclerosis models
By Sorbara et al, published by “Neuron” (Vol. 84, no. 6, December 2014)

Identical lesion morphology in primary progressive and relapsing-remitting MS–an ultrahigh field MRI study
By Kuchling et al, published by “Mult Scler.” (Vol. 20, no. 14, December 2014)

Review: Mode of action and clinical studies with fumarates in multiple sclerosis
By Salmen A and Gold R, published by “Exp Neurol.” (Vol. 262, Part A, December 2014)

Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS
By Koutrolos et al, published by “Acta Neuropathol Commun.” (Vol. 2, December 2014)

Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination
By Mohan et al, published by “Acta Neuropathol Commun.” (Vol. 2, December 2014)

Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer’s disease and frontotemporal lobar degeneration
By Oeckl et al, published by “J Proteome Res.” (Vol. 13, no. 11, November 2014)

Magnetic Resonance Imaging in Multiple Sclerosis – Patients’ Experiences, Information Interests and Responses to an Education Programme
By Brand et al, published by “PLoS One” (Vol. 9, no. 11:e113252, November 2014)

Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients
By Fleischer et al, published by “J Clin Neurol.” (Vol. 10, no. 4, October 2014)

Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation
By Beltrán et al, published by “Brain” (Vol. 137, Pt 10, October 2014)

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders
By Gnanapavan et al, published by “Neurology” (Vol. 83, no. 13, September 2014)

Review: Microglia: unique and common features with other tissue macrophages
By Prinz et al, published by “Acta Neuropathol.” (Vol. 128, no. 3, September 2014)

A unified cell biological perspective on axon-myelin injury
By Simons et al, published by “J Cell Biol.” (Vol. 206, no. 3, August 2014)

The investigation of acute optic neuritis: a review and proposed protocol
By Petzold et al, published by “Nat Rev Neurol.” (Vol. 10, no. 8, August 2014)

Human CD4+HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo
By Pankratz et al, published by “FASEB J.” (Vol. 28, no. 8, August 2014)

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells
By Schneider-Hohendorf et al, published by “J Exp Med.” (Vol. 211, Nr. 9, August 2014)

Review: Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis: In Search of Biomarkers
By Alvermann et al, published by “JAMA Neurol.” (Vol. 71, no. 7, July 2014)

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate
By Jarius et al, published by “J Neuroinflammation” (Vol. 11, no. 129, July 2014)

Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients
By Nischwitz et al, published by “Acta Neurol Scand” (Vol. 130, no. 1, July 2014)

Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions
By Schirmer et al, published by “Ann Neurol.” (Vol. 75, no. 6, June 2014)

Nurse-led immunotherapy DEcision Coaching In Multiple Sclerosis (DECIMS) – design and feasibility study for a cluster-randomised controlled trial
By Rahn et al, published by “MSJ” (Vol. 20, no. 7, June 2014)

Management of disease modifying treatments in neurological autoimmune diseases of the central nervous system
By Salmen et al, published by “Clin Exp Immunol” (Vol. 176, no. 2, May 2014)
Multiparametric optical analysis of mitochondrial redox signals during neuronal physiology and pathology in vivo
By Breckwoldt et al, published by “Nat Med.” (Vol. 20, no. 5, May 2014)

Neuromyelitis optica: clinical features, immunopathogenesis and treatment
By Jarius et al, published by “Clin Exp Immunol.” (Vol. 176, no. 2, May 2014)

Pathologic heterogeneity persists in early active multiple sclerosis lesions
By Metz et al, published by “Ann Neurol” (Vol. 75, no. 5, May 2014)

Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses
By Schweingruber et al, published by “Acta Neuropathol” (Vol. 127, no. 5, May 2014)

Review: Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
By Prinz M and Priller J, published by “J Nat Rev Neurosci.” (Vol. 15, no. 5, May 2014)

NF-κB signaling regulates myelination in the CNS
By Blank T and Prinz M, published by “Front Mol Neurosci.” (Vol. 7, no. 47, May 2014)

B cells in multiple sclerosis: good or bad guys?: An article for 28 May 2014 – World MS Day 2014
By Hoffmann F and Meinl E, published by “Eur J Immunol.” (Vol. 44, no. 5, May 2014)

Review: B cells in MS and NMO: pathogenesis and therapy
By Krumbholz M and Meinl E, published by “Semin Immunopathol.” (Vol. 36, no. 3, May 2014)

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity
By Breuer et al, published by “Ann Neurol.” (Vol. 75, no. 5, May 2014)

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants
By Sundqvist et al, published by “PLoS Pathog.” (Vol. 10, no. 4, April 2014)

Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis
By Hoepner et al, published by “J Cent Nerv Syst Dis.” (Vol. 6, April 2014)

Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis
By Senel et al, published by “PLoS One” (Vol. 9, no. 4: e88680, April 2014)

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
By Shen et al, published by “Nature” (Vol. 507, no. 7492, March 2014)

Comment: New evidence for teriflunomide in multiple sclerosis
By Kieseier BC and Wiendl H, published by “Lancet Neurol.” (Vol. 13, no. 3, March 2014)

Review: To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis
By Schirmer et al, published by “Mult Scler.” (Vol. 20, no. 3, March 2014)

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis
By Deppe et al, published by “Neuroimage Clin.” (Vol. 6, no. 4, March 2014)

The neuroinflammation biobank in the Department of Neurology, University Hospital Muenster, Germany
By Posevitz-Fejfár A and Wiendl H, published by “Biopreserv Biobank” (Vol. 12, no. 1, February 2014)

Selective accumulation of pro-inflammatory T cells in the intestine contributes to the resistance to autoimmune demyelinating disease
By Berer et al, published by “PLoS One” (Vol. 9, no. 2:e87876, February 2014)

The fraction of varicella zoster virus-specific antibodies among all intrathecally-produced antibodies discriminates between patients with varicella zoster virus reactivation and multiple sclerosis
By Otto et al, published by “Fluids Barriers CNS” (Vol. 11, no. 1:3, February 2014)

Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease
By Kraus et al, published by “Neurology” (Vol. 82, no. 6, February 2014)

Review: Biomarkers of treatment response in multiple sclerosis
By Buck D and Hemmer B, published by “Expert Rev Neurother.” (Vol. 14, no. 2, February 2014)

Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases
By Kowarik et al, published by “J Neurol.” (Vol. 261, no. 1, January 2014)

Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain
By Paul F and Wattjes MP, published by “Lancet” (Vol. 383, no. 9912, January 2014)

Onset of secondary progressive phase and long-term evolution of multiple sclerosis
By Scalfari et al, published by “J Neurol Neurosurg Psychiatry” (Vol. 85, no. 1, January 2014)

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
By International Multiple Sclerosis Genetics Consortium, published by “Nat Genet.” (Vol. 45, no. 11, November 2013)

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
By Teunissen et al, published by “Mult Scler.” (Vol. 19, no. 13, November 2013)

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis
By Warnke et al, published by “Neurology” (Vol. 81, no. 16, October 2013)

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients
By Selter et al, published by “Multiple Sclerosis Journal” (Vol. 19, no. 11, October 2013)

Hunting for autoantibodies in multiple sclerosis
By Hemmer B and Srivastava R, published by “Neurology” (Vol. 81, no. 11, September 2013)

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
By Schwab et al, published by “Neurology” (Vol. 81, no. 10, September 2013)

An assay to quantify species-specific anti-JC virus antibody levels in MS patients
By Warnke et al, published by “Mult Scler J” (Vol. 19, no. 9, August 2013)

T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients
By Balint et al, published by “Neurology” (Vol. 81, no. 9, August 2013)

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis
By Galea et al, published by “European Journal of Neurology” (Vol. 20, no. 7, July 2013)

A combination of fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real time during CNS autoimmunity
By Lodygin et al, published by “Nature Medicine” (Vol. 19, no. 6, June 2013)

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls
By International Multiple Sclerosis Genetics Consortium, published by “Am J Hum Genet” (Vol. 92, no. 6, June 2013)

Neurons as targets for T cells in the nervous system
By Liblau et al, published by “Trends in Neurosciences” (Vol. 36, no. 6, June 2013)

MANBA, CXR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis
By International Multiple Sclerosis Genetics Consortium, published by “Brain” (Vol. 136, no. 6, June 2013)

Fine-tuning of Regulatory T-Cell Function: the Role of Calcium Signals and Naïve Treg for Treg Deficiency in Multiple Sclerosis?
By Schwarz et al, published by “J Immunol” (Vol. 190, no. 10, May 2013)

Mitoxantrone-related acute leukemia in MS: an open or closed book?
By Chan A und Lo-Coco F, published by “Neurology” (Vol. 80, Nr. 16, April 2013)

Cellular, subcellular and functional in vivo labeling of the spinal cord using vital dyes
By Romanelli et al, published by “Nat Protoc.” (Vol 8, no. 3, March 2013)

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk
By Lill et al, published by “J Med Genet.” (Vol. 50, no. 3, March 2013)

Genetic Variants in the Immunoglobulin Heavy Chain Locus are Associated with the Gamma Globulin Index in Multiple Sclerosis
By Buck et al, published by “Annals of Neurology” (Vol. 73, no. 1, January 2013)

Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis
By Décard et al, published by “J Neurol Neurosurg Psychiatry” (Vol. 83, no. 12, December 2012)

Neurofascin as a target for autoantibodies in peripheral neuropathies
By Ng et al, published by “Neurology” (Vol. 79, no. 23, December 2012)

B cells and antibodies in multiple sclerosis pathogenesis and therapy
By Krumbholz et al, published by “Nat Rev Neurol” (Vol. 8, no. 11, November 2012)

Therapeutic monitoring of immunotherapies in autoimmune diseases
By von Ahsen N und Chan A, published by “Current pharmaceutical design” (Vol. 18, no. 29, October 2012)

Prospects of transcript profiling for mRNAs and MicroRNAs using formalin-fixed and paraffin-embedded dissected autoptic multiple sclerosis lesions
By Eisele et al, published by “Brain Pathol.” (Vol. 22, no. 5, September 2012)

Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects
By Lill et al, published by “J Med Genet.” (Vol. 49, no. 9, September 2012)

T cells become licensed in the lung to enter the central nervous system
By Odoardi et al, published by “Nature” (Vol. 488, no. 7413, August 2012)

Biocompatibility of a genetically encoded calcium indicator in a transgenic mouse model
By Direnberger et al, published by “Nature Communications ” (Vol. 3, no. 1031, August 2012)

Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor(+) Regulatory T Cells
By Yogev et al, published by “Immunity” (Vol. 37, no. 2, August 2012)

The ambivalent role of apoptosis in experimental autoimmune
By Reichardt HM and Lühder F, published by “Curr Pharm Des” (Vol. 18, no. 29, July 2012)

The Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis
By Srivastava et al, published by “N Eng J Med” (Vol. 367, no. 2, July 2012)

Anti-JCV antibody prevalence in a German MS cohort
By Warnke et al, published by “Multiple Sclerosis Journal” (Vol. 18, no. 7, July 2012)

Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis
By Elliott et al, published by “BRAIN” (Vol. 135, no. 6, June 2012)

Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
By Derfuss T and Meinl E, published by “Curr Opin Neurol.” (Vol. 25, no. 3, June 2012)

Single nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-ß therapy in multiple sclerosis patients
By Weber et al, published by ” The Pharmacogenomics Journal” (Vol. 12, no. 3, June 2012)

Commensal gut flora and brain autoimmunity: a love or hate affair?
By Berer et al, published by “Acta Neuropathologica” (Vol. 123, No. 5, May 2012)

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
By Kowarik et al, published by “J Neuroinflammation” (Vol. 9, no. 93, May 2012)

Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more
By Mayer et al, published by “Therapeutic Advances in Neurological Disorders” (Vol. 5, no. 3, May 2012)

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
By Trampe et al, published by “Neurology” (Vol. 78, no. 22, May 2012)

Immunological and clinical consequences of treating a patient with natalizumab
By Schwab et al, published by “Multiple Sclerosis Journal” (Vol. 18, no. 3, March 2012)

Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration
By Colombo et al, published by “The Journal of Experimental Medicine” (Vol. 209, no. 3, March 2012)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
By Metz et al, published by “Acta Neuropathologica” (Vol. 123, no. 2, February 2012)

Primary oligodendrocyte death does not elicit anti-CNS immunity
By Locatelli et al, Epub ahead of print “Nature Neuroscience” (26th February 2012)

An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis
By Schmidt et al, published by “Neuroimage” (Vol. 59, no. 4, February 2012)

Fatal PML associated with efalizumab therapy. Insights into integrin αLβ2 in JC virus control
By Schwab et al, published by “Neurology” (Vol. 78, no. 7, February 2012)

Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample
By Lill et al, published by “Neurogenetics” (Vol. 13, no. 1, February 2012)

Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination
By Lee et al, published by “Acta Neuropathologica” (Vol. 123, no. 2, February 2012)

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
By Stroet et al, published by “Therapeutic Advances in Neurological Disorders” (Vol. 5, no. 2, January 2012)

B cells undergo unique compartmentalized redistribution in multiple sclerosis
By Haas et al, published by “Journal of Autoimmunity” (Vol. 37, no. 4, December 2011)

Ion channels in autoimmune neurodegeneration
By Ehling et al, published by “FEBS letters” (Vol. 585, no. 23, December 2011)

Autoimmune disease in the brain – how to spot the culprits and how to keep them in check
By Flügel et al, published by “Journal of the Neurological Sciences” (Vol. 311, s 1 , December 2011)

Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS
By Dann et al, published by “Nature Neuroscience  ” (Vol. 15, no. 1, December 2011)

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors
By Saure et al, published by “Archives of Neurology” (Vol. 68, no. 11, November 2011)

Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
By Berer et al, published by “Nature” (Vol. 479, no. 7374, November 2011)

Pharmacogenomics in Neurology: Current State and Future Steps
By Chan et al, published by “Annals of Neurology” (Vol. 70, no. 5, November 2011)

Diagnostik der Multiplen Sklerose – 2010 Revision der Mc-Donald-Kriterien
By Klotz et al, published by “Der Nervenarzt” (Vol. 82, no. 10, October 2011)

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
By Lehmann-Horn et al, published by “Journal of Neuroinflammation” (Vol. 8, no. 146, October 2011)

Treatment of multiple sclerosis: current concepts and future perspectives
By Buck D. and Hemmer B., published by “Journal of Neurology” (Vol. 258, no. 10, October 2011)

Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab
By Warnke et al, published by “Der Nervenarzt” (Vol. 82, no. 10, October 2011)

Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis
By Schweingruber et al, published by “Journal of  Immunology” (Vol. 187, no. 8, October 2011)

ATP-Binding Cassette Transporters in Inflammatory Brain Disease
By Chan et al, published by “Current Pharmaceutical Design” (Vol. 17, no. 26, September 2011)

Age and disability accumulation in multiple sclerosis
By Scalfari et al, published by “Neurology” (Vol. 77, no. 13, September 2011)

CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats
By Miljković et al, published by “Immunobiology” (Vol. 216, no. 9, September 2011)

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
By: The International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2), published by “Nature” (Vol. 476, no. 7359, August 2011)

Association between Walking Speed and Age in Healthy, Free-Living Individuals Using Mobile Accelerometry-A Cross-Sectional Study
By Schimpl et al, published by “PLoS One” (Vol. 6, no. 8, August 2011)

Evaluation of soluble HLA-G as a biomarker for multiple sclerosis
By Waschbisch et al, published by “Neurology” (Vol. 77, no. 6, August 2011)

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
By Pröbstel et al, published by “Neurology” (Vol. 77, no. 6, August 2011)

Development and validation of a new method to measure gait d speed using mobile accelerometry
By Schimpl et al, published by “PLoS One” (Vol. 6, no. 8, August 2011)

Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels
By Bobak et al, published by “Biochimica et Biophysica Acta (BBA) – Biomembranes” (Vol. 1808, no. 8, August 2011)

Humoral autoimmunity in multiple sclerosis
By Meinl et al, published by “Journal of the Neurological Sciences” (Vol. 306, no. 1-2, July 2011)

More CLEC16A gene variants associated with multiple sclerosis
By Nischwitz et al, published by “Acta Neurologica Scandinavica” (Vol. 123, no. 6, June 2011)

Risks and benefits of multiple sclerosis therapies: need for continual assessment?
By Kieseier et al, published by “Current Opinion in Neurology” (Vol. 24, no.3, June 2011)

PML under natalizumab: Initial possibilities for risk stratification?
By Warnke et al, published by “Der Nervenarzt” (Vol. 82, no. 4, April 2011)

Long-term follow-up of patients with Neuromyelitis optica after repeated therapy with rituximab
By Pellkofer et al, published by “Neurology” (Vol. 76, no. 15, April 2011)

Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin
By Obermeier et al, published by “Journal of Neuroimmunology” (Vol. 233, no. 1-2, April 2011)

A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
By Nikic et al, published by “Nature Medicine” (Vol. 17, no. 4, April 2011)

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders
By Haghikia et al, published by “PLoS One” (Vol. 6, no. 4, April 2011)

EPIBLASTER-Fast exhaustive two-locus epistasis detection strategy using graphical processing units
By Kam-Thong et al, published by “European Journal of Human Genetics” (Vol. 19, no. 4, April 2011)

Influence of the HLA-DRB1 Genotype on antibody development to Interferon Beta in Multiple Sclerosis
By Buck et al, published by “Archives of Neurology” (Vol. 68, no. 4, April 2011)

I B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF- B in the CNS
By Raasch et al, published by “BRAIN” (Vol. 134, no. 4, April 2011)

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of MS patients
By Kowarik et al, published by “Neurology” (Vol. 76, no. 14, April 2011)

Intracerebral Human Regulatory T Cells: analysis of CD4+CD25+FOXP3+ T Cells in Brain Lesions and Cerebrospinal Fluid of Multiple Sclerosis Patients
By Fritzsching et al, published by “PLoS One” (Vol. 6, no. 3, March 2011)

The interleukin-7 receptor a chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis
By Haas et al, published by “European Journal of Immunology” (Vol. 41, no. 3, March 2011)

Is it possible to measure mobility deficits of patients suffering from multiple sclerosis?
By Schlesinger et al, published by “Klinische Neurophysiologie” (Vol. 42, no. 1, March 2011)

Therapy for Multiple Sclerosis with Monoclonal Antibodies: Updated Recommendations for the Use of Natalizumab in the Framework of an Expert’s Meeting
By Hartung et al, published by “Aktuelle Neurologie” (Vol. 38, no. 1, February 2011)

Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients
By Bittner et al, published by “Arthritis Research & Therapy” (Vol. 13, no. 1, February 2011)

Janus head: the dual role of HLA-G in CNS immunity
By Huang et al, published by “Cellular and Molecular Life Sciences”
(Vol. 68, no. 3, February 2011)

Microglia in the CNS: Immigrants from another world
By M. Prinz and A. Mildner, published by “GLIA” (Vol. 59, no. 2, February 2011)

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus
By Warnke et al, published by “Multiple Sclerosis” (Vol. 17, no. 2, February 2011)

The emerging role of miRNAs in multiple sclerosis
By Junker et al, published by “Nature Reviews Neurology” (Vol. 7, no. 1, January 2011)

Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica
By Kalluri et al, published by “PLoS One” (Vol. 6, no. 1, January 2011)

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in multiple sclerosis patients
By Schneider-Hohendorf et al, published by “European Journal of Immunology” (Vol. 40, no. 12, December 2010)

A Data Protection Scheme for Medical Research Networks: Review after Five Years of Operation
By Helbing et al, published by “Methods Inf Med” (Vol. 49, no. 6, December 2010)

Glatiramer Acetate attenuates pro-inflammatory T Cell responses but does not directly protect neurons from inflammatory cell death
By Herrmann et al, published by “American Journal of Pathology” (Vol. 177, no. 6, December 2010)

Genetic proof for the transient nature of the Th17 phenotype
By Kurschus et al, published by “European Journal of Immunology” (Vol. 40, no. 12, December 2010)

Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis
By Doerck et al, published by “Plos one” (Vol. 5, no. 11, November 2010)

ESPED 2009 – Bericht des Beirats
By Berner et al, published by “Monatsschrift Kinderheilkunde” (Vol. 158, no. 11, November 2010)

B Cells participate in thymic negative selection of murine auto-reactive CD4+ T Cells
By F. Frommer and A. Waisman, published by “Plos one” (Vol. 5, no. 10, October 2010)

Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis
By Chan et al, published by “Multiple Sclerosis Journal” (Vol. 16, no. 10, October 2010)

Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis
By Nischwitz et al, published by “Journal of Neuroimmunology” (Vol. 227, no. 1-2, October 2010)

Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica
By Kalluri et al, published by “Archives of Neurology” (Vol. 67, no. 10, October 2010)

Extracellular matrix in multiple sclerosis lesions: fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells
By Mohan et al, published by “Brain pathology” (Vol. 20, no. 5, September 2010)

T cell vaccination induces the elimination of EAE effector T cells: analysis using GFP-transduced, encephalitogenic T cells
By Volovitz et al, published by “Journal of Autoimmunity” (Vol. 35, no. 2, September 2010)

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
By Linker et al, published by “Brain” (Vol. 133, no. 8, August 2010)

A Practical guide to pediatric multiple sclerosis
By P. Huppke and J. Gärtner, published by “Neuropediatrics” (Vol. 41, no. 4, August 2010)

Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis
By Heidbrink et al, published by “Brain, Behavior, and Immunity” (Vol. 24, no. 6, August 2010)

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies
By Waschbisch et al, published by “Journal of Neuroimmunology” (Vol. 225, no. 1-2, August 2010)

Upregulation of K_2P5.1 Potassium Channels in Multiple Sclerosis
By Bittner et al, published by “Annals of Neurology” (Vol. 68, no. 1, July 2010)

Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system
By Cordiglieri et al, published by “Brain” (Vol. 133, no. 7, July 2010)

Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases
By Selter et al, published by “Neurology” (Vol. 74, no. 21, May 2010)

An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in Multiple Sclerosis
By Schwab et al, published by “Journal of Immunology” (Vol. 184, no. 9, May 2010)

Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis
By Kleiter et al, published by “Brain” (Vol. 133, no. 4, April 2010)

The antibody response to oligodendrocyte specific protein in multiple sclerosis
By Aslam et al, published by “Journal of Neuroimmunology” (Vol. 221, April 2010)

MS-Datenbank erleichtert Forschung
By Daumer et al, published by “Ärztliche Praxis Neurologie & Psychiatrie“ (no. 1, January 2010)

Knocking at the brain’s door: intravital two-photon imaging of autoreactive T cell interactions with CNS structures
By N. Kawakami and A. Flügel, published by “Seminars in Immunopathology” (Vol. 32, no. 3, September 2010)

Beneficial brain autoimmunity?
By H. Wekerle and R. Hohlfeld, published by “Brain” (Vol. 133, no. 8, August 2010)

Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury
By Derfuss et al, published by “Journal of Molecular Medicine” (Vol. 88, no. 8, August 2010)

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis
By Aktas et al, published by “Trends in Neuroscience” (Vol. 33, no. 3, March 2010)

Antibodies to Native Myelin Oligodendrocyte Glycoprotein in Children with Inflammatory Demyelinating Central Nervous System Disease
By Brilot et al, published by “Annals of Neurology” (Vol. 66, no. 6, December 2009)

Glatiramer acetate improves regulatory T-cell function by expansion of naïve CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis
By Haas et al, published by “Journal of Neuroimmunology” (Vol. 216, December 2009)

Prognosis of the individual course of disease: the elements of time, hetereogeneity and precision
By Daumer et al, published by “Journal of Neurological Sciences” (Vol. 287, November 2009)

Intrathecal Pathogenic Anti-Aquaporin-4 Antibodies in Early Neuromyelitis Optica
By Bennett et al, published by “Annals of Neurology” (Vol. 66, no. 5, November 2009)

A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis
By Comabella et al, published by “Brain” (Vol. 132, no. 12, September 2009)

Specific central nervous system recruitment of HLA-G regulatory T Cells in multiple sclerosis
By Huang et al, published by “Annals of Neurology” (Vol. 66, no. 2, August 2009)

T cell suppression by naturally occurring HLA-G-expressing regulatory CD4 T cells is IL-10-dependent and reversible
By Huang et al, published by “Journal of Leukocyte Biology” (Vol. 86, August 2009)

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis
By Cotte et al, published by “Brain” (Vol. 132, no. 9, July 2009)

The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE
By Zozulya et al, published by “European Journal of Immunology” (Vol. 39, no. 6, June 2009)

Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants
By Kroner et al, published by “The American Journal of Pathology” (Vol. 174, no. 6, June 2009)

Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory Immune Responses in the CNS
By Zozulya et al, published by “The Journal of Neuroscience” (Vol. 29, no. 1, January 2009)